Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
| ▸ | MMP14 | P50281 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18545353 | 0.99 | MMP9 (0.41) | MMP9MMP8MMP14CYP3A4CYP1A2 | |
| SCHEMBL18545352 | 0.99 | MMP9 (0.42) | MMP9MMP8MMP14CYP3A4CYP1A2 | |
| SCHEMBL16298534 | 0.94 | MMP9 (0.40) | MMP9MMP8MMP14CYP3A4CYP1A2 | |
| SCHEMBL18545354 | 0.94 | MMP9 (0.42) | MMP9MMP8MMP14CYP3A4CYP1A2 | |
| SCHEMBL9928054 | 0.93 | CYP3A4 (0.44) | MMP9MMP8MMP14CYP3A4CYP1A2 | |
| SCHEMBL9928051 | 0.93 | CYP3A4 (0.44) | MMP9MMP8MMP14CYP3A4CYP1A2 | |
| SCHEMBL9928057 | 0.93 | CYP3A4 (0.46) | MMP9MMP8MMP14CYP3A4CYP1A2 | |
| SCHEMBL9928052 | 0.93 | CYP3A4 (0.46) | MMP9MMP8MMP14CYP3A4CYP1A2 | |
| SCHEMBL16298535 | 0.91 | CYP3A4 (0.44) | MMP9MMP8MMP14CYP3A4CYP1A2 | |
| SCHEMBL9928049 | 0.91 | CYP3A4 (0.44) | MMP9MMP8MMP14CYP3A4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170050861-A1 | Reducing Aluminosilicate Scale in the Bayer Process | NALCO COMPANY (US) | 2017-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170050861-A1 | Reducing Aluminosilicate Scale in the Bayer Process | DSP, SOST, SORD | MMP9 2567/4885MMP8 2731/4885MMP14 3044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.